FGFR3 and PIK3CA are among the most frequently mutated genes in bladder tumors. We hypothesized that recurrent mutations in these genes might be caused by common carcinogenic exposures such as smoking and other factors.
We analyzed 2,816 bladder tumors with available data on FGFR3 and/or PIK3CA mutations, focusing on the most recurrent mutations detected in ≥10% of tumors. Compared to tumors with other FGFR3/PIK3CA mutations, FGFR3-Y375C was more common in tumors from smokers than never-smokers (p=0.009), while several APOBEC-type driver mutations were enriched in never-smokers: FGFR3-S249C (p=0.013) and PIK3CA-E542K/PIK3CA-E545K (p=0.009). To explore possible causes of these APOBEC-type mutations, we analyzed RNA-seq data from 798 bladder tumors and detected several viruses, with BK polyomavirus (BKPyV) being the most common. We then performed immunohistochemical (IHC) staining for polyomavirus (PyV) Large T-antigen (LTAg) in an independent set of 211 bladder tumors. Overall, by RNA-seq or IHC-LTAg, we detected PyV in 26 out of 1,010 bladder tumors with significantly higher detection (p=4.4 × 10-5), 25/554 (4.5%) in non-muscle-invasive bladder cancers (NMIBC) versus 1/456 (0.2%) of muscle-invasive bladder cancers (MIBC). In the NMIBC subset, the FGFR3/PIK3CA APOBEC-type driver mutations were detected in 94.7% (18/19) of PyV-positive vs. 68.3% (259/379) of PyV-negative tumors (p=0.011). BKPyV tumor positivity in the NMIBC subset with FGFR3- or PIK3CA-mutated tumors was also associated with a higher risk of progression to MIBC (p=0.019). In conclusion, our results support smoking and BKPyV infection as risk factors contributing to bladder tumorigenesis in the general patient population through distinct molecular mechanisms.
Cancer prevention research (Philadelphia, Pa.). 2023 Jul 20 [Epub ahead of print]
Nina Rao, Gabriel J Starrett, Mary L Piaskowski, Kelly E Butler, Yelena Golubeva, Wusheng Yan, Scott M Lawrence, Michael Dean, Montserrat Garcia-Closas, Dalsu Baris, Alison Johnson, Molly Schwenn, Nuria Malats, Francisco X Real, Manolis Kogevinas, Nathaniel Rothman, Debra T Silverman, Lars Dyrskjøt, Christopher B Buck, Stella Koutros, Ludmila Prokunina-Olsson
National Cancer Institute, Bethesda, MD, United States., National Cancer Institute, Bethesda, Maryland, United States., National Cancer Institute, Bethesda, United States., National Cancer Institute, United States., Leidos Biomedical Research Inc., Rockville, MD, United States., Leidos Biomedical Research Inc., Frederick, MD, United States., National Cancer Institute, Rockville, MD, United States., Vermont Department of Health, Burlington, Vermont, United States., Formerly of Maine Cancer Registry, Augusta, Maine, United States., Spanish National Cancer Research Centre, Madrid, Spain., Centro Nacional de Investigaciones Oncológicas, Madrid, Spain., Barcelona Institute for Global Health, Barcelona, Spain., National Cancer Institute, Rockville, United States., Aarhus University Hospital, Aarhus N, Denmark.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/37477495